# Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

> **NCT00970684** · PHASE2 · COMPLETED · sponsor: **Nathan Pennell, MD, PhD** · enrollment: 13 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00970684
- **Lead sponsor:** Nathan Pennell, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970684, "Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00970684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*